Blog
New FDA Guidance Could Speed Biosimilar Approvals and Cut Costs
Key Takeaways: The FDA released draft guidance indicating it may approve certain biosimilars without requiring a comparative efficacy study (CES), traditionally a costly and time-intensive step….
By: Polsinelli